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ABSTRACT
In light of the growing availability of ultrasound testing and invasive diagnostic methods of the breast in everyday gyneco-
logic practice, lesions of uncertain malignant potential, classified histologically as B3, have become a significant health 
issue. Intraductal papillomas (IPs) are the most common pathology in that group of lesions. Despite their benign histologic 
appearance, IPs may accompany malignant growths and the diagnosis made on the basis of biopsy material carries the 
risk of breast cancer (BC) underestimation. The article presents a review of the available literature on the management of 
patients diagnosed with intraductal papilloma at a standard core needle biopsy or vacuum-assisted core needle biopsy. The 
management is not uniform and depends not only on the verification technique or the accompanying pathological growths, 
but also on the result of clinical-pathological correlations. As it turns out, open surgical biopsy should not necessarily be 
recommended to every affected woman, and a growing number of sources have recently suggested that a control program 
would be sufficient in many cases. Thus, it is vital for gynecologists to be able to differentiate between those women who 
may be included in the annual ultrasound control program and those who require further surgical management.
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INTRODUCTION
Ultrasound imaging of the breast is one of the com-
ponents of complex gynecologic care offered to a patient. 
In Poland, as in many other European countries, gyneco-
logic care is not limited to secondary prevention of breast 
cancer, and the number of gynecologists who perform 
histopathological verification of the focal lesions using 
different biopsy techniques continues to grow. Thus, it is 
vital that they are able to interpret the histologic result of 
a biopsy, conduct clinical-pathological correlations, and 
identify those patients who require further surgical man-
agement. An intraductal papilloma (IP), a benign growth 
originating from the epithelium of the milk duct, is an ex-
ample of a problematic histologic diagnosis. Owing to 
its heterogeneity and the risk for coexisting malignant 
growths, IP is classified as B3, i.e. a lesion of uncertain 
malignant potential [1]. 
Over the last century, the management of patients di-
agnosed with IPs has undergone a radical change. Initially, 
clinical suspicion of IP, with an accompanying sanguinous 
nipple discharge, was a direct indication for mastectomy. 
In the years to follow, segmental resection of the breast 
tissue, removal of the papillary tissue or isolated resection 
of the milk ducts, have been recommended [2]. The above-
mentioned radical management was directly responsible 
why nipple discharge, especially sanguinous, was believed 
to be indicative of malignant neoplasm of the breast for 
decades. Nowadays, in the era of advanced diagnostic 
techniques and minimally invasive procedures, the number 
of indications for surgical management of IP has notably 
decreased. Apparently, open surgical biopsy should not 
necessarily be recommended to all patients with IP and 
numerous publications suggest that follow-up program 
would be sufficient in many cases.
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EPIDEmIOlOgy
Intraductal papillomas (IPs) constitute approximately 
10% of all benign growths within the breast [3]. Their inci-
dence has been estimated at 2–3% among the female popu-
lation, but the risk increases to 40–70% in case of nipple 
discharge [4]. Papillomas may develop in women of all ages, 
most often between 30–77 years of age [5]. Almost 90% of 
IPs are central, single lesions localized within the large col-
lective ducts, usually developing in the older women and 
manifesting as nipple discharge (serous, serosanguinous, 
or sanguinous) [6]. Coexisting atypical growths are rare and 
IPs do not significantly increase the risk for the develop-
ment of BC (breast cancer) [7]. Peripheral papillomas are 
significantly less common; they usually develop in young 
women and typically have multiple, occasionally bilateral, 
presentation. They may present as palpable tumors but are 
most often clinically silent, and are diagnosed accidentally 
during preventive screening tests [8]. Unlike central papillo-
mas, they usually coexist with atypical growths, e.g. atypical 
ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), 
lobular carcinoma in situ (LCIS), or even ductal carcinoma 
in situ (DCIS), and notably increase the risk for developing 
invasive breast cancer [8–10].
UlTRASOUND AND PATHOlOgy DIAgNOSIS
Intraductal papillomas have various imaging presenta-
tions, from hyperechogenic growths in the ducts or cysts, 
to hypoechogenic, well-differentiated hypervascular solid 
masses [5, 11]. In some cases, IP morphology may resemble 
that of clustered breast microcysts [12] (Fig. 1).
As far as pathology is concerned, papillary lesions in-
clude hyperplastic lesions, presumably benign or malig-
nant tumors. Benign presumed neoplastic papillary lesions 
include large duct papilloma, peripheral duct papilloma, 
sclerosing papilloma, nipple adenoma, papilloma with 
low-grade neoplastic atypia and rare adenomyoepithelioma 
with papillary morphology [13, 14]. Structurally, they bear re-
semblance to papillary malignant lesions such as low-grade 
papillary DCIS, encapsulated papillary carcinoma or solid 
papillary carcinoma, and the use of immunohistochemistry 
is required in differential diagnosis [14]. Significant hetero-
geneity of papillary lesions is the reason why fine needle 
aspiration biopsy is not applicable in the diagnosis of IPs 
(high rate of false negative results), and even core needle 
biopsy presents a challenge for the pathologist [14]. In con-
trast, a vacuum-assisted core needle biopsy may generate 
an almost unlimited number of specimens. In terms of tis-
sue volume, vacuum-assisted core needle biopsy is more 
similar to surgical biopsy than core needle biopsy, and its 
diagnostic accuracy reaches 98–100% [15]. Nevertheless, 
material fragmentation makes it impossible to determine 
the histologic evaluation of resection margins.
INTRADUCTAl PAPIllOmA DIAgNOSED AT 
BIOPSy — THE NExT STEPS
The diagnosis of intraductal papilloma at biopsy requires 
careful management. First, sample representativeness needs 
to be evaluated, followed by the analysis of adequate clin-
ical-pathological correlations, meaning that a reanalysis of 
the biopsy material needs to be performed to verify whether 
the result corresponds to the most probable diagnosis made 
on the basis of the imaging tests. That particular course of 
action is undertaken due to the significant heterogeneity of 
the lesions in question. In case of doubt, the biopsy should 
be repeated, or surgical excision should be performed.
The method of verification is the next parameter to be 
considered. The literature reports indicate that the diagno-
sis of intraductal papilloma without atypia at a standard 
core needle biopsy is associated with a 2.3–16% risk of 
BC underestimation [16, 17]. Despite the fact that some 
authors, in case of clinical pathological concordance, ad-
vocate in favor of follow-up program [18], most clinicians 
lean towards radical local excision, either with the use of 
vacuum-assisted core biopsy or open surgical biopsy [19, 
20]. When IP is accompanied by atypical ductal hyperpla-
sia, the risk for BC underestimation increases to 13–92%, 
in which case surgical excision is common practice [3, 21]. 
The rate of false negative results for breast cancer at core 
needle biopsy is distinctly lower and has been estimated at 
0%–2.6% for IPs without atypia [22, 23], and at 9–21% for IPs 
with accompanying atypia [24, 25]. According to the current 
recommendations, surgical excision is still mandatory in case 
of atypical lesions, whereas vacuum-assisted core needle 
biopsy may be considered as a therapeutic option in case 
of IPs without atypia, on condition that a 5-year follow-up 
program is implemented [21, 22] (Fig. 2).
Figure 1. Intraductal breast papilloma images in ultrasound  
a —clustered microcysts; b — hyperechogenic mural nodule in the 
major milk duct; c — hyperechogenic growth in the cyst;  
d — hypoechogenic solid mass
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CONClUSIONS
According to the literature, after the diagnosis of IP 
without atypia at a standard core needle biopsy, surgical 
excision, either using vacuum-assisted core needle biopsy or 
open surgical biopsy, should be immediately recommended. 
Both methods have high reliability and although the biopsy 
method does not allow for histologic evaluation of the re-
section margins, lower invasiveness of the procedure is 
an undeniable asset. In case of primary vacuum-assisted 
core needle biopsy and clinical pathological concordance, 
the management may be considered as definitive. Still, it is 
vital to remember about the annual ultrasound follow-up for 
the affected women, not only due to the risk for recurrence 
but also for the development of breast cancer. Regardless of 
the verification method, the diagnosis of intraductal papil-
loma with atypia at biopsy is always and without question 
an indication for further surgical management.
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